^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vesanoid (tretinoin)

    i
    Other names: ATRA, Ro 5488, NSC 122758, NSC-122758, Ro-5488, NSC122758, Ro5488
    Company:
    Roche
    Drug class:
    Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist
    Related drugs:
    1m
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    1m
    Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
    P2, N=76, Terminated, Mario Negri Institute for Pharmacological Research | N=112 --> 76 | Trial completion date: Sep 2024 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2025; Low enrolment rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    anastrozole • Vesanoid (tretinoin)
    2ms
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    3ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    4ms
    KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=90 --> 146
    Trial completion • Enrollment change
    |
    Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    4ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Suspended, Dwight Owen | Recruiting --> Suspended
    Trial suspension
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    5ms
    KEYMAKER-U02 Substudy 02A: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=100, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=200 --> 100 | Trial completion date: Apr 2030 --> Aug 2025 | Trial primary completion date: Apr 2030 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Vesanoid (tretinoin) • quavonlimab (MK-1308) • vibostolimab (MK-7684)
    5ms
    KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Oct 2025 | Trial primary completion date: Apr 2030 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    5ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dwight Owen | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    8ms
    Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=80, Enrolling by invitation, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Enrolling by invitation | Trial completion date: Dec 2022 --> Oct 2027 | Trial primary completion date: Dec 2021 --> May 2026
    Enrollment status • Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    |
    cytarabine • Vesanoid (tretinoin) • arsenic trioxide
    11ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dwight Owen | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    11ms
    Lysari: Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (clinicaltrials.gov)
    P3, N=460, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Erbitux (cetuximab) • cisplatin • Vesanoid (tretinoin)